TEDA TIANJIN, China--(BUSINESS WIRE)--In line with Asymchem’s continuous strategic layout and development, the organization has welcomed Dr. Cheng Yi Chen as a senior executive.

中国天津泰达-（商业新闻短讯）--根据Asymchem不断的战略布局和发展，该组织欢迎Cheng Yi Chen博士担任高级管理人员。

Dr. Cheng Yi Chen officially joined Asymchem as CTO of the Small-Molecule Sector on June 18, 2024. He will report directly to Asymchem’s CEO, Dr. Hao Hong. In this position, Dr. Cheng Yi Chen will provide technical support to the group’s chemical small molecule sales in the European and United States markets.

Cheng Yi Chen博士于2024年6月18日正式加入Asymchem，担任小分子领域的首席技术官。他将直接向Asymchem首席执行官郝红博士报告。在此职位上，Cheng Yi Chen博士将为集团在欧洲和美国市场的化学小分子销售提供技术支持。

His main duties include active participation in technical communications for key mid-to-late-stage clinical projects in Europe and United States and facilitating collaborations with crucial new clients by capitalizing on the overall technical capabilities of the group’s chemical small-molecule sector.

他的主要职责包括积极参与欧洲和美国关键中晚期临床项目的技术交流，并利用集团化学小分子部门的整体技术能力，促进与关键新客户的合作。

He will also offer guidance to the China Core Team on project-related technical matters with European and United States clientele and provide advisory input for communication. Additionally, he will provide technical expertise suggestions for the Boston site in the United States, as well as supervising technical operations at small-molecule laboratories and pilot production sites across Europe..

他还将与欧洲和美国客户就项目相关技术事宜为中国核心团队提供指导，并为沟通提供咨询意见。此外，他将为美国波士顿工厂提供技术专业建议，并监督欧洲各地小分子实验室和试点生产基地的技术运营。。

Dr. Chen worked at Merck Research Laboratories, Janssen Pharmaceuticals of Johnson & Johnson, Mirati Therapeutics, and Bristol Myers Squibb before joining Asymchem. He has extensive experience designing, developing, and implementing robust, cost-effective, and green manufacturing routes for small molecule APIs, ensuring CMC compliance and quality, collaborating with cross-functional drug development teams and external partners, and supporting regulatory filings.

在加入Asymchem之前，陈博士曾在默克研究实验室、强生杨森制药公司、米拉蒂治疗公司和百时美施贵宝公司工作。他在设计、开发和实施稳健、经济高效、绿色的小分子原料药生产路线、确保CMC合规性和质量、与跨职能药物开发团队和外部合作伙伴合作以及支持监管备案方面拥有丰富经验。

Dr. Chen received his Ph.D. in organic chemistry from The Ohio State University..

陈博士在俄亥俄州立大学获得有机化学博士学位。。

About Asymchem

关于Asymchem

Asymchem is a comprehensive contract development and manufacturing organization (CDMO) with a complete continuum of support from preclinical to commercialization. Founded in 1997, Asymchem offers integrated solutions spanning the entire drug substance and drug product life cycle, backed by cutting-edge technology including flow chemistry and green manufacturing.

Asymchem是一家综合合同开发和制造组织（CDMO），拥有从临床前到商业化的完整连续支持。Asymchem成立于1997年，以包括流动化学和绿色制造在内的尖端技术为支持，提供跨越整个原料药和药品生命周期的集成解决方案。

With R&D and manufacturing operations in China, Europe, and the U.S. and a team of proven experts, we provide a full range of CDMO services for a global client base..

凭借在中国、欧洲和美国的研发和制造业务，以及一支经验丰富的专家团队，我们为全球客户群提供全方位的CDMO服务。。